Concord Biotech Limited — Investor Meet, 21-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance**: Concord Biotech reported revenues of INR 244 crore for Q3 FY25, marking a slight increase compared to INR 240 crore in Q3 FY24, reflecting a 1% growth. The EBITDA stood at INR 98 crore, with margins at 40.1%, while the profit after tax was INR 76 crore, translating to a PAT margin of 31.1%. For the nine months ending December 31, 2024, revenues increased by 10% year-on-year to INR 770 crore, driven largely by a 42% rise in formulation revenues, despite a 3% growth in API revenues.

**Future Outlook and Growth Drivers**: The management maintains a positive outlook, targeting a 25% CAGR over the next five years. They are focusing on expanding their product portfolio, particularly through the introduction of 8-10 new products over the next three years, with strong emphasis on oncology and anti-infective segments. Overall, the strategy aims at leveraging their strengths in both domestic and emerging markets.

**Order Book and Operational Updates**: The order book remains robust, driven by a strategic shift in customer procurement that has seen some orders pushed from Q3 to Q4. This reflects anticipated strong revenue generation in the upcoming quarter. The formulation revenue for Q3 FY25 was impacted by year-end closures in several international markets but is expected to rebound as new tenders come into play.

**Analyst Q&A Insights (Detailed)**:

- **Revenue and Profitability**: Analysts raised concerns regarding the growth projections for the fiscal year, given the recent performance. Management indicated that Q4 growth will likely be better due to a strong order book and positive January results.

- **Market Position and Competitive Landscape**: There were inquiries about competitive pressures in the API market. Management clarified that while market dynamics may fluctuate, they have not lost market share, as demand remains strong for their products.

- **Operational Challenges or Risks**: Questions were raised about potential delays in customer orders. Management acknowledged these but expressed confidence in the eventual recovery and execution of orders.

- **Capex and Capital Allocation**: Analysts queried about Capex plans. Management confirmed minimal growth Capex with ongoing investments focused primarily on the newly operational injectable plant.

- **Strategic Priorities and Long-Term Vision**: Discussions centered on Concord's CDMO business opportunities. Management sees CDMO as a medium-term growth driver, supported by increased inquiries and RFQs.

**Market or Regulatory Updates**: The company is actively transitioning to renewable energy, which is expected to contribute positively to operational costs and sustainability goals.

**Strategic Focus Areas**: The overarching theme remains a commitment to innovation, sustainability, and leveraging existing market capabilities. Management's tone reflected optimism regarding growth in both the domestic and export markets, especially following the launch of new products.

**Investor Insight**: Given the strong financial position and strategic initiatives underway, including the upcoming launch of the injectable facility, there is potential for continued growth. The observed financial stability and market positioning suggest a favorable view, aligning more closely with a ‘buy’ stance, assuming successful execution of growth strategies and order fulfillment in the upcoming quarters.